Sunday, 22 November 2026 Every SEC filing alert, by company
ALFAFINDER USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Bioxytran Q3 2026 Results: Net Loss of $1.28M, Loss Widens

Bioxytran, Inc. reported a net loss of $3,966,754 for the nine months ended September 30, 2026, compared to a loss of $1,600,922 in the prior year period, driven largely by a significant increase in general and administrative expenses related to affiliates. The company's cash position decreased to $74,369 as of September 30, 2026, while total liabilities nearly doubled to $6.46 million due to increases in un-issued shares liabilities and derivative liabilities.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Profit before tax-1.3-0.3
Net income-1.3-0.3
EPS (diluted, $ a share)$-0.00$-0.00

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Source

10-Q filed with the SEC, OTC: BIXT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Bioxytran, Inc: key numbers

Share price
$0.0220Close, Nov 20
Market cap
$2.52M
Shares outstanding
114.7MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Bioxytran, Inc

All →
3:44 PM ET 8-K
Product Launch

Bioxytran Product Launch

Bioxytran, Inc. announced the commercial launch of its first two nutraceutical products, A-SUQAR for metabolic support and V-LO for immune support. The launch marks the clinical-stage biotech's expansion into the consumer wellness market, utilizing its carbohydrate-chemistry expertise. Both products are available immediately through the company's online storefront.

“For years, our team has worked on complex therapeutics for critical care and infectious diseases. Today we are bringing that same science directly to people’s doorsteps. Our entry into nutraceuticals is driven by a simple principle: apply rigorous scientific standards to everyday health. We have held these products to the same diligence we apply to our drug programs, so consumers get a high-quality, science-backed supplement they can trust.”

David Platt, Ph.D., Chief Executive Officer of Bioxytran
6:04 AM ET 8-K
Regulatory Approval

Bioxytran Regulatory Approval

Bioxytran secured a government-issued Free Sale Certificate for its A-SUQAR chewable nutraceutical, a key regulatory milestone for market entry in the UAE and Gulf Cooperation Council region. The certification confirms the product is lawfully manufactured and sold as a health supplement, allowing the company to proceed with product registration in markets with high diabetes prevalence.

Get Alerts

Get ALFAFINDER USA alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.